Report overview
Calcium antagonists are a group of medications that disrupt the movement of calcium (Ca2+) through calcium channels. Calcium channel blockers are used as antihypertensive drugs, i.e., as medications to decrease blood pressure in patients with hypertension. CCBs are particularly effective against large vessel stiffness, one of the common causes of elevated systolic blood pressure in elderly patients. Calcium channel blockers are also frequently used to alter heart rate (especially from atrial fibrillation), to prevent peripheral and cerebral vasospasm, and to reduce chest pain caused by angina pectoris.
N-type, L-type, and T-type voltage-dependent calcium channels are present in the zona glomerulosa of the human adrenal gland, and CCBs can directly influence the biosynthesis of aldosterone in adrenocortical cells, with consequent impact on the clinical treatment of hypertension with these agents.
CCBs have been shown to be slightly more effective than beta blockers at lowering cardiovascular mortality, but they are associated with more side effects. Potential major risks however were mainly found to be associated with short-acting CCBs.
This report aims to provide a comprehensive presentation of the global market for Calcium Antagonists, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Calcium Antagonists. This report contains market size and forecasts of Calcium Antagonists in global, including the following market information:
Global Calcium Antagonists Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Calcium Antagonists Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Calcium Antagonists companies in 2022 (%)
The global Calcium Antagonists market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Dihydropyridine Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Calcium Antagonists include Pfizer, Aventis, Searle, Bayer, AstraZeneca, Knoll Pharmaceuticals, Wyeth-Ayerst, Novartis and Sanofi, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Calcium Antagonists manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Calcium Antagonists Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Calcium Antagonists Market Segment Percentages, by Type, 2022 (%)
Dihydropyridine
Diltiazem
Verapamil
Others
Global Calcium Antagonists Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Calcium Antagonists Market Segment Percentages, by Application, 2022 (%)
Hypertension
Coronary Artery Disease
Arrhythmia
Ohers
Global Calcium Antagonists Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Calcium Antagonists Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Calcium Antagonists revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Calcium Antagonists revenues share in global market, 2022 (%)
Key companies Calcium Antagonists sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Calcium Antagonists sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Aventis
Searle
Bayer
AstraZeneca
Knoll Pharmaceuticals
Wyeth-Ayerst
Novartis
Sanofi
Baiyunshan Pharmaceutical
South China Pharmaceutical Group
Tianjin Tanabe Seiyaku
Outline of Major Chapters:
Chapter 1: Introduces the definition of Calcium Antagonists, market overview.
Chapter 2: Global Calcium Antagonists market size in revenue and volume.
Chapter 3: Detailed analysis of Calcium Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Calcium Antagonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Calcium Antagonists capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
